The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Hypoxia-Inducible Factor as an Angiogenic Master Switch
Open accessAbstract
Hypoxia-inducible factors (HIFs) regulate the transcription of genes that mediate the response to hypoxia. HIFs are constantly expressed and degraded under normoxia, but stabilized under hypoxia. HIFs have been widely studied in physiological and pathological conditions and have been shown to contribute to the pathogenesis of various vascular diseases. In clinical settings, the HIF pathway has been studied for its role in inhibiting carcinogenesis. HIFs might also play a protective role in the pathology of ischemic diseases. Clinical trials of therapeutic angiogenesis after the administration of a single growth factor have yielded unsatisfactory or controversial results, possibly because the coordinated activity of different HIF-induced factors is necessary to induce mature vessel formation. Thus, manipulation of HIF activity to simultaneously induce a spectrum of angiogenic factors offers a superior strategy for therapeutic angiogenesis. Because HIF-2α plays an essential role in vascular remodeling, manipulation of HIF-2α is a promising approach to the treatment of ischemic diseases caused by arterial obstruction, where insufficient development of collateral vessels impedes effective therapy. Eukaryotic initiation factor 3 subunit e (eIF3e)/INT6 interacts specifically with HIF-2α and induces the proteasome inhibitor-sensitive degradation of HIF-2α, independent of hypoxia and von Hippel-Lindau protein. Treatment with eIF3e/INT6 siRNA stabilizes HIF-2α activity even under normoxic conditions and induces the expression of several angiogenic factors, at levels sufficient to produce functional arteries and veins in vivo. We have demonstrated that administration of eIF3e/INT6 siRNA to ischemic limbs or cold-injured brains reduces ischemic damage in animal models. This review summarizes the current understanding of the relationship between HIFs and vascular diseases. We also discuss novel oxygen-independent regulatory proteins that bind HIF-α and the implications of a new method for therapeutic angiogenesis using HIF stabilizers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 2×
“Other HIF downstream genes regulate processes such as glucose uptake, glycolysis, angiogenesis, vascular remodeling, extracellularmatrixmetabolism, inflammation, cell proliferation, apoptosis, autophagy, migration and invasion, DNA damage responses, and survival (3, 12, 13).”
BackgroundWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Colman (2022) · doi:10.1073/pnas · Cited by 4,370
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
Cited by
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00633-y · Cited by 326
Chen, R., Lai, U. H., Zhu, L., Singh, A., Ahmed, M., & Forsyth, N. R. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00132 · Cited by 269
Ravenna, L., Salvatori, L., & Russo, M. A. (2016) · The FEBS Journal · doi:10.1111/febs.13572 · Cited by 97
Klimkiewicz, K., Weglarczyk, K., Collet, G., Paprocka, M., Guichard, A., Sarna, M., Jozkowicz, A., Dulak, J., Sarna, T., Grillon, C., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.006 · Cited by 70
“When a solid tumour develops, the first step of the stroma establishment occurs with the involvement of the endothelial cells that are prompted to form vessels by the angiogenic switch upon hypoxia establishment in the tumour mass [32].”
BackgroundAdipose tissue aging is regulated by an altered immune system
Zhang, Y.-X., Ou, M.-Y., Yang, Z.-H., Sun, Y., Li, Q.-F., & Zhou, S.-B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125395 · Cited by 62
“On the one hand, the activation of HIF1a inhibits preadipocyte differentiation and initiates adipose tissue fibrosis.”
BackgroundInfluentialRegulation of hypoxia-inducible factor functions in the nucleus by sphingosine-1-phosphate
Hait, N. C., Maiti, A., Xu, P., Qi, Q., Kawaguchi, T., Okano, M., Takabe, K., Yan, L., & Luo, C. (2020) · The FASEB Journal · doi:10.1096/fj.201901734rr · Cited by 41
Transcriptional profiling of normal, stenotic, and regurgitant human aortic valves
Greene, C. L., Jaatinen, K. J., Wang, H., Koyano, T. K., Bilbao, M. S., & Woo, Y. J. (2020) · Genes · doi:10.3390/genes11070789 · Cited by 30
Metadata
- Authors
- Hashimoto, T., & Shibasaki, F.
- Venue
- Frontiers in Pediatrics
- Publisher
- Frontiers Media SA
- Published
- 2015-04-24
- Volume
- 3
- Pages
- 33-33
- ISSN
- 2296-2360 (ISSN-L)
- OpenAlex
- W2012520088
- Cited by
- 231
- References
- 43
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.